| Literature DB >> 34357435 |
Takayoshi Tachibana1, Junya Kanda2,3, Takuma Ishizaki4, Yuho Najima5, Masatsugu Tanaka6, Noriko Doki5, Shin-Ichiro Fujiwara7, Shun-Ichi Kimura2, Makoto Onizuka8, Satoshi Takahashi9, Takeshi Saito10, Takehiko Mori11, Shin Fujisawa12, Emiko Sakaida13, Takuya Miyazaki14, Nobuyuki Aotsuka15, Moritaka Gotoh16, Reiko Watanabe17, Katsuhiro Shono18, Heiwa Kanamori6, Yoshinobu Kanda2,7, Shinichiro Okamoto11.
Abstract
The efficacy and clinical significance of pre-conditioning intervention (PCI) before allogeneic hematopoietic cell transplantation (HCT) in patients with acute lymphoblastic leukemia (ALL) not in remission remain inconclusive. The purpose of this multicenter retrospective study was to clarify the clinical significance of PCI before HCT in patients with non-remission ALL. Patients with non-remission ALL who received HCT between 2005 and 2015 at 16 institutions were included. PCI was objectively defined and classified to three groups according to the intensity of PCI (no, intensive, or moderate). The study cohort consisted of 104 patients with a median age of 38 (range 17-68). A significant decrease of blast percentage in the peripheral blood (PB) was confirmed in both PCI groups, suggesting that PCIs were effective to stabilize the disease activity. The group with moderate PCI had higher nucleated cell count in the BM compared to the group with intensive PCI or the group without PCI. The overall survival (OS) rates of groups with intensive and no PCI showed comparable and significantly better compared to the group with moderate PCI (P = 0.009). Multivariate analysis demonstrated that the OS of moderate PCI group was significantly worse compared to that of intensive PCI group (HR = 2.43, 95% CI: 1.32-4.14, P = 0.004), while the OS of intensive PCI group was comparable to that of the group without PCI. These results suggest that the intensity of PCI rather than the response to PCI may contribute to improve the transplant outcome in patients with ALL not in remission.Entities:
Keywords: Acute lymphoblastic leukemia; Pre-conditioning intervention; Refractory; Relapse
Year: 2021 PMID: 34357435 DOI: 10.1007/s00277-021-04607-8
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673